PHARNEXT Email Format

Biotechnology ResearchÎle-de-france, France11-50 Employees

Pharnext is a biotechnology company focused on developing therapeutics for neurodegenerative diseases where curative or disease-modifying options are lacking. Its lead program PXT3003 targets Charcot–Marie–Tooth disease type 1A and has completed an international Phase III trial with favorable topline results, and it holds orphan drug status in Europe and the United States. A pivotal Phase III study in CMT1A, named PREMIER, is currently under way, while a second lead asset, PXT864, has shown encouraging Phase II results in Alzheimer's disease and is expected to advance through partnerships.

Pharnext operates in the biotechnology research sector from Suresnes, near Paris, France, and is listed on the Euronext Growth market. Its work originates from Pleotherapy, the company's R&D approach, and targets patients with neurodegenerative conditions where current treatment options remain limited.

Sign up for free to view info

Company overview Employee directory